Bausch + Lomb, Novaliq Receive FDA Approval for Dry Eye Disease Treatment
Miebo reported as the first cleared remedy that directly targets tear evaporation.
Bausch + Lomb, a global eye care company, and Novaliq, a biopharmaceutical company, have officially announced that the FDA has approved Miebo, a treatment for dry eye disease. Reportedly, the medication is the first and only FDA-approved treatment that directly targets tear evaporation.
“Today’s FDA approval of MIEBO further advances dry eye disease treatment by addressing a significant unmet need for millions of people suffering with this disease,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “We are proud to bring to market the first and only prescription eye drop approved in the United States for the treatment of dry eye disease that directly targets evaporation. We expect to make MIEBO commercially available in the second half of this year.”
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
